Swiss double Covid vaccine order from Pfizer/BioNTech
Switzerland has ordered enough to vaccinate the population more than two times over.
Keystone / Fazry Ismail
The Swiss government has signed a new deal with Pfizer/BioNTech for another three million vaccine doses, bringing the total number of doses ordered from five companies to nearly 36 million.
The additional doses will be delivered to Switzerland in April, according to the government. When announcing the “good news”, health minister Alain Berset tweeted that “one million (doses) will already be available in the cantons in April, May and June”.
This comes amid concerns about the slow pace of the vaccine rollout. To date, only 1.3 million doses have been delivered and around 3.8% of the population has been fully vaccinated. As a comparison, in Israel, which has about the same population as Switzerland, more than 40% of the population is fully vaccinated.
During a press conference yesterday, Nora Kronig, deputy director of the Federal Office of Public Health, said vaccinations were still progressing according to plan. “We are still confident that by the end of June we will be able to vaccinate anyone who wants to,” Kronig told reporters.
Spreading its purchases
Switzerland has so far bought more than 35 million doses for its population of 8.6 million. These doses are from five manufacturers: Moderna (13.5 million doses), Pfizer/BioNTech (now around 6 million), Oxford/AstraZeneca (around 5.3 million), Curevac (5 million) and Novavax (6 million).
In a statementExternal link, the government said “given that production and availability of vaccines are subject to such great uncertainty, the federal government continues to look into different vaccine technologies from different vaccine manufacturers”. However, it is focusing on mRNA vaccines because they are “proving to be highly effective and well tolerated”. Four out of the five vaccines ordered are mRNA-based.
So far, only the Pfizer and Moderna vaccines have been approved by the Swiss medical regulator Swissmedic. CureVac and Novavax have not yet filed for approval and Oxford/AstraZeneca’s vaccine is still being reviewed. Swissmedic has said that based on the available data, the safety, efficacy and quality of the vaccine could not be conclusively evaluated. It is still awaiting results of large-scale clinical trials from Oxford/AstraZeneca.
Popular Stories
More
Climate solutions
Switzerland turns train tracks into solar power plants
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Vast majority of Swiss support social media ban for under-16s
This content was published on
Around 80% of people who took part in a recent survey in Switzerland said they were in favour of a social media ban for under-16s.
Koyo Kouoh, prominent art world figure, dies aged 58
This content was published on
Koyo Kouoh, curator of the 61st International Art Exhibition of La Biennale di Venezia, Biennale Arte 2026, has died, aged 58, it was announced on Saturday.
This content was published on
One in seven adults in Switzerland has fallen victim to a cyber scam, according to a survey published by the SonntagsZeitung newspaper. One-third of victims have lost over CHF1,000 ($1,200).
Treasury secretary says Swiss firms want to invest up to CHF200 billion in US
This content was published on
According to US Treasury Secretary Scott Bessent, Swiss companies have indicated their interest in investing CHF150-200 billion ($180-240 billion) in the United States.
Trump hails ‘great progress’ at US-China trade talks in Geneva
This content was published on
US President Donald Trump on Saturday welcomed the "great progress" made at talks between the US and China in Geneva on tariffs.
Switzerland plans to open Venice’s Palazzo Trevisan to wider audience
This content was published on
The Swiss foreign ministry is taking over the management of the Palazzo Trevisan in Venice, which until now had been overseen mainly by the Swiss Arts Council, Pro Helvetia.
United States and China start tariff talks in Geneva
This content was published on
The United States and China have started talks in Geneva aiming to de-escalate a dispute that threatens to cut off trade between the world’s two biggest economies and damage the global economy.
Switzerland takes over investigation into SWISS emergency landing in Austria
This content was published on
Following the emergency landing of a Swiss International Air Lines (SWISS) plane in Austria last December, during which a crew member died, Austria has now handed over the investigation to Switzerland.
‘September 5’ takes top honours at German Film Awards
This content was published on
Swiss director Tim Fehlbaum's real-life thriller September 5, based on the terrorist attacks on the 1972 Munich Olympics, has won the Golden Lola.
Switzerland and US agree to accelerate tariff talks
This content was published on
After a meeting with US ministers in Geneva on Friday, the Swiss president intends to present Washington with a declaration of intent in the next two weeks.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
This content was published on
Switzerland will be affected by the temporary delay to the Pfizer-BioNTech Covid-19 vaccine in Europe, the Swiss health authorities have confirmed.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.